Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 15/20 | 0.45 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | STS | P08842 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1936860 | 0.94 | TGFBR1 (0.43) | FAAHGPR119TGFBR1MEN1KMT2A | |
| SCHEMBL1936320 | 0.89 | TGFBR1 (0.44) | GPR119TGFBR1MEN1KMT2ASTS | |
| SCHEMBL2541058 | 0.85 | CCR5 (0.41) | — | |
| SCHEMBL3397674 | 0.84 | PTPRB (0.48) | MEN1KMT2ASTS | |
| Fumaric Acid SCHEMBL2548804 | 0.80 | CCR5 (0.38) | — | |
| SCHEMBL2544643 | 0.79 | SLC6A4 (0.47) | FAAH | |
| SCHEMBL1937237 | 0.78 | HTR4 (0.43) | — | |
| SCHEMBL2539468 | 0.77 | GPR119 (0.67) | FAAHGPR119MEN1KMT2A | |
| Fumaric Acid SCHEMBL2548144 | 0.74 | SLC6A4 (0.43) | — | |
| SCHEMBL2452509 | 0.74 | CCR3 (0.52) | GPR119STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263651-A1 | NOVEL PIPERIDINE-BUTYRAMIDE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2011-10-27 | — | — | US | disclosed |
| WO-2010060852-A1 | NOVEL PIPERIDINE-BUTYRAMIDE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2010-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263651-A1 | NOVEL PIPERIDINE-BUTYRAMIDE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | SLC18A2, SLC6A2, SLC18A3 | FAAH 149/4885GPR119 373/4885TGFBR1 3445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.